PMID- 29880523
OWN - NLM
STAT- MEDLINE
DCOM- 20190605
LR  - 20190605
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 75
IP  - 12
DP  - 2018 Jun 15
TI  - Herpes zoster subunit vaccine for the prevention of herpes zoster.
PG  - 861-869
LID - 10.2146/ajhp170399 [doi]
AB  - PURPOSE: Published literature on the efficacy and safety of the herpes zoster 
      (HZ) subunit vaccine (HZ/su vaccine) in reducing the risks of HZ and postherpetic 
      neuralgia (PHN) in adults 50 years of age and older, as well as the vaccine's 
      properties and efficacy relative to live attenuated vaccine, is reviewed. 
      SUMMARY: HZ/su vaccine (Shingrix, GlaxoSmithKline) is a recently Food and Drug 
      Administration (FDA)-approved vaccine indicated for the prevention of HZ in 
      adults 50 years of age and older. Based on several Phase III trials, the Advisory 
      Committee on Immunization Practices has preferentially recommended HZ/su vaccine 
      over a live attenuated vaccine previously approved by FDA. Reported overall HZ/su 
      vaccine efficacy in preventing HZ in Phase III trials ranged from 89.8% to 97.2%. 
      Compared with placebo use, HZ/su vaccine in those trials was associated with 
      higher rates of transient local and systemic adverse events (AEs) but similar 
      rates of serious vaccine-related AEs. Other clinical trials of HZ/su vaccine have 
      yielded favorable results in various populations, including adults with a history 
      of HZ, older adults who previously received live attenuated zoster vaccine, 
      adults with human immunodeficiency virus infection, and stem cell transplant 
      recipients. CONCLUSION: HZ/su vaccine is a recently approved, preferred option to 
      reduce the risks of HZ and PHN in adults 50 years of age or older. Pain at the 
      injection site is the most common AE associated with use of the vaccine.
CI  - Copyright (c) 2018 by the American Society of Health-System Pharmacists, Inc. All 
      rights reserved.
FAU - Symoniak, Melanie R
AU  - Symoniak MR
AD  - Department of Pharmacy Practice and Administration, Wegmans School of Pharmacy, 
      St. John Fisher College, Rochester, NY msymoniak@sjfc.edu.
AD  - Department of Pharmacy, Rochester General Hospital, Rochester, NY. 
      msymoniak@sjfc.edu.
FAU - Farrokh, Pejman
AU  - Farrokh P
AD  - Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY.
FAU - Gandhi, Mona A
AU  - Gandhi MA
AD  - Department of Pharmacy Practice and Administration, Wegmans School of Pharmacy, 
      St. John Fisher College, Rochester, NY.
FAU - Slish, Judianne C
AU  - Slish JC
AD  - Department of Pharmacy Practice and Administration, Wegmans School of Pharmacy, 
      St. John Fisher College, Rochester, NY.
AD  - Department of Pharmacy, UR Medicine Highland Hospital, Rochester, NY.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Herpes Zoster Vaccine)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Clinical Trials as Topic/methods
MH  - Herpes Zoster/epidemiology/*prevention & control
MH  - Herpes Zoster Vaccine/*administration & dosage
MH  - Humans
MH  - Middle Aged
MH  - Neuralgia, Postherpetic/epidemiology/*prevention & control
MH  - Vaccines, Subunit/administration & dosage
OTO - NOTNLM
OT  - HZ/su vaccine
OT  - herpes zoster
OT  - herpes zoster subunit vaccine
OT  - postherpetic neuralgia
OT  - shingles
OT  - zoster vaccine live
EDAT- 2018/06/09 06:00
MHDA- 2019/06/06 06:00
CRDT- 2018/06/09 06:00
PHST- 2018/06/09 06:00 [entrez]
PHST- 2018/06/09 06:00 [pubmed]
PHST- 2019/06/06 06:00 [medline]
AID - 75/12/861 [pii]
AID - 10.2146/ajhp170399 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2018 Jun 15;75(12):861-869. doi: 10.2146/ajhp170399.